Aingo Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.25 Cr
as on 16-11-2024
- Satisfied Charges ₹ 2.40 M
as on 16-11-2024
- Revenue 5.21%
(FY 2023)
- Profit 2.00%
(FY 2023)
- Ebitda -3.65%
(FY 2023)
- Net Worth 30.85%
(FY 2023)
- Total Assets 1.46%
(FY 2023)
About Aingo Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.25 Cr. The company has closed loans amounting to ₹2.40 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Garg and Ram Gopal serve as directors at the Company.
- CIN/LLPIN
U24232CH2013PTC034743
- Company No.
034743
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aingo Pharma Private Limited offer?
Aingo Pharma Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Pharma & Bioanalytical Services, PCD Pharma Franchise, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Osteoporosis Medications, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Aingo Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Garg  | Director | 18-Aug-2014 | Current |
| Ram Gopal | Director | 05-Dec-2014 | Current |
Financial Performance of Aingo Pharma.
Aingo Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.21% increase. The company also saw a slight improvement in profitability, with a 2% increase in profit. The company's net worth Soared by an impressive increase of 30.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aingo Pharma?
In 2023, Aingo Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Apr 2024 | ₹7.50 M | Open |
Others Creation Date: 13 Oct 2023 | ₹5.00 M | Open |
Hdfc Bank Limited Creation Date: 31 Jan 2017 | ₹2.40 M | Satisfied |
How Many Employees Work at Aingo Pharma?
Unlock and access historical data on people associated with Aingo Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aingo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aingo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
